BRAF V600E, Glioblastoma, Glioma, Pleomorphic Xantho-Astrocytoma
Conditions
Brief summary
This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.
Detailed description
The primary goal of this study is to establish concentrations of dabrafenib and trametinib in enhancing brain tissue and cerebrospinal fluid from people with BRAF-V600E mutant recurrent gliomas who undergo tumor resection. The exploratory goals are to measure the amount of ERK signaling pathway activity, to identify mechanisms of resistance to these drugs, and evaluate feasibility of measuring tumor DNA in cerebrospinal fluid. People (adults or children) with brain tumors who are already taking dabrafenib and / or trametinib and are in need of a surgical resection are potentially eligible. On the day of surgery, blood, cerebrospinal fluid, and tumor tissue will be collected for research purposes.
Interventions
PROCEDURESurgical Cohort
Blood, cerebrospinal fluid, and surgical tissue collected during procedure
Sponsors
Musella Foundation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Weeks to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must have a history of primary brain tumor (including but not limited to glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic ganglioglioma (AG), and anaplastic pleomorphic xanthoastrocytoma (PXA)). * Subjects must have a BRAF-V600 mutation identified in previous tissue analysis (may be IHC or PCR based). Allowable mutations include V600E, V600K, V600R, and V600D. * Subjects must be taking dabrafenib at a dose of at least 50mg twice daily (adults only) and / or trametinib at a dose of at least 1mg daily (adults only) for at least 7 days prior to surgery as prescribed by their treating physician. Note: Pediatric patients may be taking any dose of dabrafenib and / or trametinib as prescribed by their treating physician for at least 7 days prior to surgery. * Subjects must be undergoing surgery for clinical purposes. * Written informed consent - a signed informed consent and/or assent (as age appropriate) for study participation will be obtained according to institutional guidelines.
Exclusion criteria
* Subjects who are receiving any other investigational agents or chemotherapeutic agents. * Subjects for whom collection of blood, spinal fluid, or tissue samples is unsafe or clinically inadvisable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of dabrafenib in brain tumor | Day 1 | Obtain single time-point concentration of dabrafenib in enhancing brain tissue (ng/mL) using liquid chromatography/mass spectrometry with one single, random sample |
| Concentration of trametinib in brain tumor | Day 1 | Obtain single time-point concentration of trametinib in enhancing brain tissue (ng/mL) using liquid chromatography/mass spectrometry with one single, random sample |
Countries
United States
Outcome results
None listed